Literature DB >> 24169510

Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy.

James A McCubrey1, Nicole M Davis2, Stephen L Abrams2, Giuseppe Montalto3, Melchiorre Cervello4, Jorg Basecke5, Massimo Libra6, Ferdinando Nicoletti6, Lucio Cocco7, Alberto M Martelli8, Linda S Steelman2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24169510     DOI： 10.1016/j.jbior.2013.09.013

Source DB:  PubMed          Journal:  Adv Biol Regul        ISSN： 2212-4926


× No keyword cloud information.
  30 in total

Review 1.  The therapeutic potential of mTOR inhibitors in breast cancer.

Authors:  Linda S Steelman; Alberto M Martelli; Lucio Cocco; Massimo Libra; Ferdinando Nicoletti; Stephen L Abrams; James A McCubrey
Journal:  Br J Clin Pharmacol       Date:  2016-05-10       Impact factor: 4.335

Review 2.  mTOR-targeted cancer therapy: great target but disappointing clinical outcomes, why?

Authors:  Shi-Yong Sun
Journal:  Front Med       Date:  2020-11-09       Impact factor: 4.592

Review 3.  Casein Kinase II (CK2), Glycogen Synthase Kinase-3 (GSK-3) and Ikaros mediated regulation of leukemia.

Authors:  Chandrika Gowda; Mario Soliman; Malika Kapadia; Yali Ding; Kimberly Payne; Sinisa Dovat
Journal:  Adv Biol Regul       Date:  2017-06-13

4.  Glycogen synthase kinase-3 inhibitor AR-A014418 suppresses pancreatic cancer cell growth via inhibition of GSK-3-mediated Notch1 expression.

Authors:  Selvi Kunnimalaiyaan; T Clark Gamblin; Muthusamy Kunnimalaiyaan
Journal:  HPB (Oxford)       Date:  2015-07-06       Impact factor: 3.647

5.  GSK-3β mediates ischemia-reperfusion injury by regulating autophagy in DCD liver allografts.

Authors:  Tingting Liu; Yang Han; Wu Lv; Pan Qi; Wenshi Liu; Ying Cheng; Jianan Yu; Yongfeng Liu
Journal:  Int J Clin Exp Pathol       Date:  2019-02-01

6.  Combined regulation of mTORC1 and lysosomal acidification by GSK-3 suppresses autophagy and contributes to cancer cell growth.

Authors:  I Azoulay-Alfaguter; R Elya; L Avrahami; A Katz; H Eldar-Finkelman
Journal:  Oncogene       Date:  2014-12-15       Impact factor: 9.867

Review 7.  Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.

Authors:  Nicole M Davis; Melissa Sokolosky; Kristin Stadelman; Steve L Abrams; Massimo Libra; Saverio Candido; Ferdinando Nicoletti; Jerry Polesel; Roberta Maestro; Antonino D'Assoro; Lyudmyla Drobot; Dariusz Rakus; Agnieszka Gizak; Piotr Laidler; Joanna Dulińska-Litewka; Joerg Basecke; Sanja Mijatovic; Danijela Maksimovic-Ivanic; Giuseppe Montalto; Melchiorre Cervello; Timothy L Fitzgerald; Zoya Demidenko; Alberto M Martelli; Lucio Cocco; Linda S Steelman; James A McCubrey
Journal:  Oncotarget       Date:  2014-07-15

Review 8.  Glycogen synthase kinase-3β: a novel therapeutic target for pancreatic cancer.

Authors:  Li Ding; Daniel D Billadeau
Journal:  Expert Opin Ther Targets       Date:  2020-03-21       Impact factor: 6.902

9.  Multi-objective de novo drug design with conditional graph generative model.

Authors:  Yibo Li; Liangren Zhang; Zhenming Liu
Journal:  J Cheminform       Date:  2018-07-24       Impact factor: 5.514

10.  Quantitative phosphoproteome analysis of embryonic stem cell differentiation toward blood.

Authors:  Manuela Piazzi; Andrew Williamson; Chia-Fang Lee; Stella Pearson; Georges Lacaud; Valerie Kouskoff; James A McCubrey; Lucio Cocco; Anthony D Whetton
Journal:  Oncotarget       Date:  2015-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.